Bruno CLEMENT, DR
Research topics and scientific objectives
Education and main positions held
After a Ph.D. in Cellular and Molecular Biology, Bruno Clément joined the NIH in Bethesda MD, as a post-doctoral fellow for 3 years. In 1985, he was appointed at Inserm in the “Liver research Unit”, and in 1992, he became Research Director of the Microenvironment and Tumor Progression team. Appointed director of the Inserm unit ‘Liver, Metabolism and Cancer’ in 2010, he is currently Director of the Institute ‘Nutrition, Metabolism and Cancer’ (Inserm-Inra-University of Rennes) since 2017. His work was focused on the physiopathology of the liver, the role of the microenvironment in the onset and progression of hepatocellular carcinoma and the development of innovative diagnosis and therapeutic tools for the treatment of liver diseases (167 publications ; h-index = 41 ; 6 patents). He was member of the editorial board of Hepatology in 1997-2007. From 1998 to 2003, Bruno Clément was appointed at the Ministry of Research as a counselor in the Biotechnology department, being involved in the implementation of the Law on Innovation, through dedicated actions in favor of biotechnology, including the first national program for biobanks. He was member of several international committees on biobanks and biotechnology, e.g. in OECD and in the European Commission. From 2003 to 2007, Bruno Clément was appointed counselor of the general director of Inserm for biobanks and biotechnology development, and scientific director of INSERM-Transfert. He was co-founder of the national network of liver Biological research centers in 2002, and CSO of the National Biobanks Infrastructure from 2011 to 2016. Bruno Clément is a corresponding member of the National Academy of Medicine.
See more : http://cvscience.aviesan.fr/cv/1179/bruno-clement